Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw

[1] Marx RE(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic J Oral Maxillofac Surg 61 1115-1117

[2] Kulkarni R(2014)Antiresorptive related osteonecrosis of the jaw bone (ARONJ); a single maxillofacial unit case series and analysis Br J Oral Maxillofac Surg 52 74-82

[3] Cymerman J(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosisi of the jaw-2014 update J Oral Maxillofac Surg 72 1938-1956

[4] Pick A(2001)Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy; a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558-567

[5] Ruggiero SL(2003)American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042-4047

[6] Dodson TB(2002)A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458-1468

[7] Fantasia J(2004)Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 879-882

[8] Major P(2015)Diagnosis and management of osteonecrosis of the jaw: a systemic review and international consensus J Bone Miner Res 30 3-23

[9] Lorholary A(2017)Adjudication of osteonecrosis of the jaw in phaseIII randerminzed controlled trials of denosumab: a systematic review Eur J Clin Pharmacol 73 517-523

[10] Hillner BE(2017)Case-based review of osteonecrosis of the jaw(ONJ) and application of the international recommendations for management from the international task force on ONJ J Clin Densitom 20 8-24

[1] Marx RE(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic J Oral Maxillofac Surg 61 1115-1117

[2] Kulkarni R(2014)Antiresorptive related osteonecrosis of the jaw bone (ARONJ); a single maxillofacial unit case series and analysis Br J Oral Maxillofac Surg 52 74-82

[3] Cymerman J(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosisi of the jaw-2014 update J Oral Maxillofac Surg 72 1938-1956

[4] Pick A(2001)Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy; a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558-567

[5] Ruggiero SL(2003)American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042-4047

[6] Dodson TB(2002)A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458-1468

[7] Fantasia J(2004)Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 879-882

[8] Major P(2015)Diagnosis and management of osteonecrosis of the jaw: a systemic review and international consensus J Bone Miner Res 30 3-23

[9] Lorholary A(2017)Adjudication of osteonecrosis of the jaw in phaseIII randerminzed controlled trials of denosumab: a systematic review Eur J Clin Pharmacol 73 517-523

[10] Hillner BE(2017)Case-based review of osteonecrosis of the jaw(ONJ) and application of the international recommendations for management from the international task force on ONJ J Clin Densitom 20 8-24